After Stenting in Afib, Xarelto-Based Anticoagulation Reduces Bleeding

ACC Conference Reporter

AHA 2016 | NEW ORLEANS — After stenting patients with atrial fibrillation (Afib), a course of rivaroxaban (Xarelto) -- in combination with either a P2Y12 inhibitor or dual antiplatelet therapy (DAPT) -- was safer than a warfarin-DAPT combination, a late-breaking trial showed. Read More >>>

Keywords: AHA Annual Scientific Sessions, AHA16

< Back to Listings